Evidence map›Paper›PMID 34786070›Full record

ArticleAmerican journal of translational research2021

A novel silicone derivative of natural osalmid (DCZ0858) exerts anti-multiple myeloma activity by promoting cell apoptosis and inhibiting cell cycle and mTOR signaling.

Wenxuan Bu, Bo Li, Lijin Feng, Qilin Feng, Ke Hu, Zhijian Xu, Yingcong Wang, Mengyu Xi, Houcai Wang, Guang Yang and 3 more

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Wenxuan BuDepartment of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine Shanghai 200072, China.
Bo LiCAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences Shanghai 201203, China.
Lijin FengDepartment of Pathology, Shanghai Tenth People's Hospital, Tongji University School of Medicine Shanghai 200072, China.
Qilin FengDepartment of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine Shanghai 200072, China.
Ke HuNanjing Medical University Nanjing 211100, China.
Zhijian XuCAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences Shanghai 201203, China.
Yingcong WangDepartment of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine Shanghai 200072, China.
Mengyu XiCAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences Shanghai 201203, China.
Houcai WangDepartment of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine Shanghai 200072, China.
Guang YangDepartment of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine Shanghai 200072, China.
Xiaosong WuDepartment of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine Shanghai 200072, China.
Weiliang ZhuCAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences Shanghai 201203, China.
Jumei ShiDepartment of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine Shanghai 200072, China.
Shanghai Tenth People's Hospital · CNChinese Academy of Sciences · CNTongji University · CNNanjing Medical University · CNShanghai Institute of Materia Medica · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma (MM) is a malignant disease characterized by abnormal proliferation of clonal plasma cells. Based on the organic drug osalmid, the novel small molecule compound DCZ0858 was designed and synthesized for treating MM. DCZ0858 inhibited the proliferation and activity of MM cells and reduced colony formation. It also promoted the apoptosis of primary cells from patients with MM and cultured MM cell lines but had little effect on peripheral blood mononuclear cells in healthy people. Simultaneously, DCZ0858 activated caspase family proteins, blocked MM cells in G0/G1 phase, and reduced the expression of related cyclins CDK4/6 and CyclinD1. Moreover, DCZ0858 overcame the protective effect of the bone marrow microenvironment and effectively inhibited the activity of mTORC1 and mTORC2. Further, xenograft model experiments in mice showed that DCZ0858 significantly inhibited the proliferation and growth of tumors, with low drug toxicity. These results indicate that DCZ0858 has marked anti-MM activity and little effect on normal cells and tissues, making it a new candidate clinical drug for the treatment of MM.

Indexed as

bone marrow microenvironmentcell apoptosiscell proliferationDCZ0858mTORMultiple myeloma

Identifiers

PMID34786070
PMCPMC8581878
OpenAlexW3212359385

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.